title: Cost-Utility Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-To-Severe Active Rheumatoid Arthritis In Greece.
authors.affiliation: National School of Public Health, Athens, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Tzanetakos
authors.affiliation: National School of Public Health, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Maniadakis
authors.affiliation: Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Kourlaba
authors.affiliation: Athens Medical School, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Tzioufas
authors.affiliation: Athens Medical School, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Goules
authors.affiliation: UCB Pharma, Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Theodoratou
authors.affiliation: UCB Pharma, Athens, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Christou